Tearsheet
Investment Highlights Market Valuation Price Chart About PFE Interactive Breakdown Better Bets vs. PFE Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Pfizer (PFE)

Market Price (10/16/2025): $24.43 | Market Cap: $138.9 Bil
Sector: Health Care | Industry: Pharmaceuticals

Pfizer (PFE)

Market Price (10/16/2025): $24.43
Market Cap: $138.9 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 13%, Dividend Yield is 5.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 8.5%, FCF Yield is 9.0%		 Weak multi-year price returns
2Y Excs Rtn is -69%, 3Y Excs Rtn is -116%		 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -12%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19%, CFO LTM is 15 Bil, FCF LTM is 12 Bil		  
3 Low stock price volatility
Vol 12M is 26%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 13%, Dividend Yield is 5.2%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 8.5%, FCF Yield is 9.0%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 26%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19%, CFO LTM is 15 Bil, FCF LTM is 12 Bil
3 Low stock price volatility
Vol 12M is 26%
4 Weak multi-year price returns
2Y Excs Rtn is -69%, 3Y Excs Rtn is -116%
5 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -12%

Market Valuation & Key Metrics

PFES&P 500
REVENUE GROWTH 
Rev LTM ($ Bil)63.8
Rev Chg Q10.3%6.2%
Rev Chg LTM13.5%5.2%
Rev Chg 3Y Avg-12.4%5.4%
PROFITABILITYGOOD
Op Inc LTM ($ Bil)16.7
Op Mgn LTM26.1%18.6%
CFO LTM ($ Bil)15.2
CFO/Rev LTM23.8%20.3%
Net Inc LTM ($ Bil)10.8
Net Inc Mgn16.8%12.7%
VALUATIONLOW
P/S2.23.3
P/CFO9.215.9
P/FCF11.220.8
P/E12.924.0
STABILITYGOOD
Debt/Equity0.440.21
Cash/Assets0.060.07

PFE Stock

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
PFE Return-2%67%-10%-41%-2%-3%-17%
Peers Return9%21%17%5%9%9%91%
S&P 500 Return16%27%-19%24%23%13%103%

Monthly Win Rates [3]
PFE Win Rate33%75%42%17%33%44% 
Peers Win Rate52%55%60%45%48%56% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
PFE Max Drawdown-27%-8%-28%-47%-11%-17% 
Peers Max Drawdown-20%-7%-10%-17%-10%-13% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: RHHBY, LLY, JNJ, MRK, BMY. See PFE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/15/2025 (YTD)

Downturns Compared

Unique KeyEventPFES&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-57.3%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven134.4%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-30.0%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven42.9%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven254 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-25.9%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven35.0%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven727 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-57.9%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven137.4%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1429 days1480 days


How Low Can It Go?

Pfizer's stock fell -57.3% during the 2022 Inflation Shock from a high on 12/16/2021. A -57.3% loss requires a 134.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

Interactive Breakdown

Pfizer Interactive Breakdown Analysis

Better Bets than Pfizer (PFE)

 PFEBetter Performance than PFE
MetricValueIndustry (Pharmaceuticals)
Rev Chg LTM13.5%LLY (36.8%), CORT (25.7%), ACAD (14.4%), KNSA (56.2%), ALVO (82.6%)
Rev Chg 3Y Avg-12.4%LLY (23.4%), JNJ (4.0%), MRK (3.7%), BMY (0.5%), ZTS (5.5%)
Op Mgn LTM26.1%LLY (43.0%), MRK (31.2%), ZTS (37.5%), PBH (31.2%), INVA (47.7%)
CFO/Rev LTM23.8%JNJ (25.4%), MRK (29.1%), BMY (30.0%), ZTS (31.2%), JAZZ (32.2%)
FCF/Rev LTM19.5%MRK (23.1%), BMY (27.5%), ZTS (23.6%), JAZZ (30.3%), CORT (25.2%)
Total Yield13.0%OGN (37.4%), SIGA (13.7%), EBS (26.8%), INCR (26.5%)
 PFEBetter Performance than PFE
MetricValueAll Other Sectors
Rev Chg LTM13.5%NVDA (71.6%), MSFT (14.9%), META (19.4%), AVGO (28.0%), NFLX (14.8%)
Rev Chg 3Y Avg-12.4%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM26.1%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM23.8%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM19.5%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), META (30.7%), AVGO (41.6%)
Total Yield13.0%BABA (38.0%), TM (2152.5%), VZ (17.3%), TD (15.1%), CMCSA (18.4%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Day 8 of Loss Streak for Pfizer Stock with -11% Return (vs. -3.1% YTD) [10/15/2025]Notification 
2Pfizer Earnings Notes  
3Day 7 of Loss Streak for Pfizer Stock with -10% Return (vs. -2.6% YTD) [10/14/2025]Notification 
4Ten-Year Tally: PFE Returns $100 Bil to Shareholders  
5Day 6 of Loss Streak for Pfizer Stock with -9.6% Return (vs. -1.8% YTD) [10/13/2025]Notification 
6Time To Buy Pfizer Stock?Buy or Fear 
7Pfizer vs Royalty Pharma: Which Is A Better Investment?Counter-Intuitive Comparisons 
8Pfizer vs Innoviva: Which Is A Better Investment?Counter-Intuitive Comparisons 
9With 47% Gains On The Table, LLY May Outshine PFEActionable 
10PFE's 5.2% One Day Pop Begs The Question: Is INVA Better Instead?Counter-Intuitive Comparisons 
11ARTICLES  
12Pfizer Stock Pays Out $50 Bil to Investors in 10 Years October 14th, 2025
13PFE Surges 6.8% In A Single Day, Time To Buy The Stock? October 2nd, 2025
14Is Pfizer Stock A Buy At $25? October 1st, 2025
15S&P 500 Movers | Winners: PFE, MRK, DHR | Losers: ALB, MGM, COF October 1st, 2025
16PFE Has Paid Out $50 Bil to Investors in the Past Decade September 6th, 2025
Title
0DASHBOARDS
1Pfizer Stock Pays Out $50 Bil to Investors in 10 Years
2PFE Surges 6.8% In A Single Day, Time To Buy The Stock?
3Is Pfizer Stock A Buy At $25?
4S&P 500 Movers | Winners: PFE, MRK, DHR | Losers: ALB, MGM, COF
5PFE Has Paid Out $50 Bil to Investors in the Past Decade
6ARTICLES
7Day 8 of Loss Streak for Pfizer Stock with -11% Return (vs. -3.1% YTD) [10/15/2025]
8Pfizer Earnings Notes
9Day 7 of Loss Streak for Pfizer Stock with -10% Return (vs. -2.6% YTD) [10/14/2025]
10Ten-Year Tally: PFE Returns $100 Bil to Shareholders
11Day 6 of Loss Streak for Pfizer Stock with -9.6% Return (vs. -1.8% YTD) [10/13/2025]
12Time To Buy Pfizer Stock?
13Pfizer vs Royalty Pharma: Which Is A Better Investment?
14Pfizer vs Innoviva: Which Is A Better Investment?
15With 47% Gains On The Table, LLY May Outshine PFE
16PFE's 5.2% One Day Pop Begs The Question: Is INVA Better Instead?

Trade Ideas

Select past ideas related to PFE. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.9%2.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.5%2.5%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		0.9%0.9%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		10.5%10.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-6.7%-6.7%-8.0%
PFE_5312025_Monopoly_xInd_xCD_Getting_Cheaper05312025PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		5.6%5.6%-1.6%
PFE_2282023_Monopoly_xInd_xCD_Getting_Cheaper02282023PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-8.9%-29.9%-33.3%
PFE_8312022_Monopoly_xInd_xCD_Getting_Cheaper08312022PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-9.6%-18.6%-19.5%
PFE_2282022_Monopoly_xInd_xCD_Getting_Cheaper02282022PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.1%-10.6%-10.6%
PFE_3312020_Monopoly_xInd_xCD_Getting_Cheaper03312020PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.0%15.6%-2.7%
PFE_9302019_Monopoly_xInd_xCD_Getting_Cheaper09302019PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-7.3%4.7%-19.1%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.9%2.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.5%2.5%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		0.9%0.9%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		10.5%10.5%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-6.7%-6.7%-8.0%
PFE_5312025_Monopoly_xInd_xCD_Getting_Cheaper05312025PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		5.6%5.6%-1.6%
PFE_2282023_Monopoly_xInd_xCD_Getting_Cheaper02282023PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-8.9%-29.9%-33.3%
PFE_8312022_Monopoly_xInd_xCD_Getting_Cheaper08312022PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-9.6%-18.6%-19.5%
PFE_2282022_Monopoly_xInd_xCD_Getting_Cheaper02282022PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.1%-10.6%-10.6%
PFE_3312020_Monopoly_xInd_xCD_Getting_Cheaper03312020PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		13.0%15.6%-2.7%
PFE_9302019_Monopoly_xInd_xCD_Getting_Cheaper09302019PFEPfizerMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-7.3%4.7%-19.1%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NVTSNavitas Semiconductor95.9%324.6%
2BITFBitfarms61.7%334.2%
3UAMYUnited States Antimony44.5%677.4%
4GLUEMonte Rosa Therapeutics44.1%60.1%
5FLNCFluence Energy43.3%35.0%
6SMRNuScale Power39.9%198.0%
7UUUUEnergy Fuels38.8%387.1%
8ASPIASP Isotopes38.5%178.6%
9MVSTMicrovast38.3%201.9%
10TNGXTango Therapeutics37.8%208.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1BNTBrookfield Wealth Solutions-33.6%18.5%
2BNBrookfield-33.4%18.9%
3VGVenture Global-29.9% 
4SOCSable Offshore-29.1%-38.3%
5HELEHelen Of Troy-28.5%-67.0%
6ALABAstera Labs-26.4%21.9%
7AIVApartment Investment & Management-26.1%-33.8%
8BBBYBed Bath & Beyond-25.7% 
9USNAUsana Health Sciences-22.6%-42.9%
10FWRDForward Air-18.0%-38.0%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1213.0%386.9%
2QUREuniQure334.2%255.8%
3LACLithium Americas193.2%217.8%
4FLNCFluence Energy185.9%35.0%
5RGTIRigetti Computing181.7%269.2%
6SESSES AI176.6%61.6%
7UAMYUnited States Antimony158.6%677.4%
8NVTSNavitas Semiconductor157.4%324.6%
9ASTSAST SpaceMobile136.7%353.5%
10QBTSD-Wave Quantum135.9%433.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1ANGXAngel Studios-46.4% 
2SOCSable Offshore-37.0%-38.3%
3VGVenture Global-35.1% 
4USNAUsana Health Sciences-32.9%-42.9%
5FLYFirefly Aerospace-32.5% 
6ALABAstera Labs-32.4%21.9%
7FWRDForward Air-31.7%-38.0%
8LDIloanDepot-29.5%53.4%
9AIVApartment Investment & Management-28.4%-33.8%
10PGYPagaya Technologies-28.1%222.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1NVTSNavitas Semiconductor95.9%324.6%
2BITFBitfarms61.7%334.2%
3UAMYUnited States Antimony44.5%677.4%
4GLUEMonte Rosa Therapeutics44.1%60.1%
5FLNCFluence Energy43.3%35.0%
6SMRNuScale Power39.9%198.0%
7UUUUEnergy Fuels38.8%387.1%
8ASPIASP Isotopes38.5%178.6%
9MVSTMicrovast38.3%201.9%
10TNGXTango Therapeutics37.8%208.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1BNTBrookfield Wealth Solutions-33.6%18.5%
2BNBrookfield-33.4%18.9%
3VGVenture Global-29.9% 
4SOCSable Offshore-29.1%-38.3%
5HELEHelen Of Troy-28.5%-67.0%
6ALABAstera Labs-26.4%21.9%
7AIVApartment Investment & Management-26.1%-33.8%
8BBBYBed Bath & Beyond-25.7% 
9USNAUsana Health Sciences-22.6%-42.9%
10FWRDForward Air-18.0%-38.0%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Pfizer

Financials

PFERHHBYLLYJNJMRKBMYMedian
NamePfizer Roche Eli LillyJohnson .Merck Bristol-. 
Mkt Price24.3944.48826.57191.1784.1143.6164.30
Mkt Cap138.7-742.2460.0211.188.6211.1
Rev LTM63,833-53,25890,62763,61647,63663,616
Op Inc LTM16,663-22,88222,22819,8217,87019,821
FCF LTM12,438--5016,39714,72213,08613,086
FCF 3Y Avg9,304--15616,92612,89912,22512,225
CFO LTM15,188-10,93823,02818,53414,31015,188
CFO 3Y Avg12,584-7,23022,24816,76613,41913,419

Growth & Margins

PFERHHBYLLYJNJMRKBMYMedian
NamePfizer Roche Eli LillyJohnson .Merck Bristol-. 
Rev Chg LTM13.5%-36.8%4.7%1.8%4.6%4.7%
Rev Chg 3Y Avg-12.4%-23.4%4.0%3.7%0.5%3.7%
Rev Chg Q10.3%-37.6%5.8%-1.9%-5.6%5.8%
QoQ Delta Rev Chg LTM2.2%-8.7%1.5%-0.5%-1.4%1.5%
Op Mgn LTM26.1%-43.0%24.5%31.2%16.5%26.1%
Op Mgn 3Y Avg20.2%-35.6%26.3%22.6%17.3%22.6%
QoQ Delta Op Mgn LTM1.8%-1.8%-0.2%-0.8%4.3%1.8%
CFO/Rev LTM23.8%-20.5%25.4%29.1%30.0%25.4%
CFO/Rev 3Y Avg18.8%-17.8%25.7%27.2%28.9%25.7%
FCF/Rev LTM19.5%--0.1%18.1%23.1%27.5%19.5%
FCF/Rev 3Y Avg13.8%-0.5%19.6%20.9%26.4%19.6%

Valuation

PFERHHBYLLYJNJMRKBMYMedian
NamePfizer Roche Eli LillyJohnson .Merck Bristol-. 
Mkt Cap138.7-742.2460.0211.188.6211.1
P/S2.2-13.95.13.31.93.3
P/EBIT10.4-41.816.310.310.910.9
P/E12.9-53.820.312.916.316.3
P/CFO9.1-67.920.011.46.211.4
Total Yield13.0%-2.5%7.6%11.6%11.7%11.6%
Dividend Yield5.2%-0.7%2.6%3.8%5.5%3.8%
FCF Yield 3Y Avg5.7%-0.1%4.5%5.1%12.4%5.1%
D/E0.4-0.10.10.20.60.2
Net D/E0.3-0.00.10.10.40.1

Returns

PFERHHBYLLYJNJMRKBMYMedian
NamePfizer Roche Eli LillyJohnson .Merck Bristol-. 
1M Rtn1.8%8.5%10.5%7.8%3.8%-4.6%5.8%
3M Rtn0.8%10.6%4.9%16.9%3.0%-6.3%4.0%
6M Rtn14.7%15.3%13.0%26.2%12.2%-9.3%13.8%
12M Rtn-11.3%16.8%-8.8%20.3%-21.8%-13.2%-10.1%
3Y Rtn-32.9%27.8%155.8%27.4%-0.2%-29.5%13.6%
1M Excs Rtn1.1%7.1%7.1%7.4%2.8%-5.6%4.9%
3M Excs Rtn-5.0%5.6%2.8%12.2%-1.7%-13.9%0.6%
6M Excs Rtn-10.9%-8.1%-14.0%2.8%-14.2%-34.0%-12.5%
12M Excs Rtn-25.2%2.6%-25.4%7.5%-35.2%-27.0%-25.3%
3Y Excs Rtn-115.8%-55.3%77.0%-54.1%-83.0%-111.9%-69.1%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/29/20253/30/202512/31/20249/29/20246/30/20243/31/202412/31/202310/1/20237/2/20234/2/202312/31/202210/2/2022
Filing Date8/5/20255/5/20252/27/202511/4/20248/5/20245/8/20242/22/202411/8/20238/9/20235/10/20232/23/202311/9/2022
Key Financials Quarterly            
Total Revenue14,65313,71517,76417,70113,28314,87814,56913,49213,00618,48525,13522,638
Ebitda5,3235,0572,5207,2532,4065,947-1,771-1,0974,3508,0757,06310,495
Operating Income3,7674,4253,1875,2842,2634,203-1,651-2,9482,4406,5736,0969,666
Net Income2,9102,9674104,465413,115-3,369-2,3822,3275,5434,9948,608
EPS0.510.520.070.790.010.55-0.60-0.420.410.980.891.54
Key Financials TTM            
Total Revenue TTM63,83362,46363,62660,43156,22255,94559,55270,11879,26494,000101,17699,879
Ebitda TTM20,15317,23618,12613,8355,4857,4299,55718,39129,98338,54841,03239,447
Operating Income TTM16,66315,15914,93710,0991,8672,0444,41412,16124,77534,74438,11937,618
Net Income TTM10,7527,8838,0314,252-2,595-3092,11910,48221,47229,05131,37229,771
Growth Rates Quarterly            
Total Revenue Growth10.3%-7.8%21.9%31.2%2.1%-19.5%-42.0%-40.4%-53.1%-28.0%5.4%-5.8%
EBITDA Growth121.2%-15.0%242.3%761.2%-44.7%-26.4%-125.1%-110.5%-66.3%-23.5%28.9%10.4%
Operating Income Growth66.5%5.3%293.0%279.2%-7.3%-36.1%-127.1%-130.5%-80.3%-33.9%9.0%27.9%
Net Income Growth6997.6%-4.8%112.2%287.4%-98.2%-43.8%-167.5%-127.7%-76.5%-29.5%47.2%5.7%
Margins Quarterly            
EBITDA Margin36.3%36.9%14.2%41.0%18.1%40.0%-12.2%-8.1%33.4%43.7%28.1%46.4%
Operating Income Margin25.7%32.3%17.9%29.9%17.0%28.2%-11.3%-21.8%18.8%35.6%24.3%42.7%
Net Income Margin19.9%21.6%2.3%25.2%0.3%20.9%-23.1%-17.7%17.9%30.0%19.9%38.0%
Cash & Debt            
Total Cash13,24917,31620,4779,9527,10111,92912,69044,18144,78519,97222,73236,123
Total Debt60,92661,29163,64966,61768,67768,70870,84563,59665,34134,92734,85935,677
Net Debt / (Cash)47,67743,97543,17256,66561,57656,77958,15519,41520,55614,95512,127-446
Cash Flows Quarterly            
FCF from Operations-5822,3356,7216,714-1,7811,0905,2403,456-1,2081,2128,5825,974
Cash Flows TTM            
FCF from Operations TTM15,18813,98912,74411,2638,0058,5788,70012,04214,56023,93829,26726,599
Returns to Shareholders Quarterly            
Dividends2,4452,4372,3802,3802,3802,3722,3152,3142,3152,3032,2452,245
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC30.1%40.3%29.5%35.4%14.7%27.1%-9.2%-43.3%47.5%155.8%192.2%-
Return on Invested Capital (ROIC) TTM            
ROIC TTM34.9%34.5%34.6%17.8%1.9%0.5%7.6%62.6%114.0%211.4%284.2%-

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Biopharma58,23799,82679,55740,72438,013
Other business activities1,3161,3491,7319262,892
Total59,553101,17581,28841,65040,905


Price Behavior

PFE Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta0.53-0.21-0.000.530.430.43
Up Beta-0.26-0.11-0.210.340.350.37
Down Beta-3.08-1.22-0.610.750.600.58
Up Capture105%37%37%48%21%7%
Bmk +ve Days13233574144420
Stock +ve Days12263467125354
Down Capture124%-57%2%73%56%78%
Bmk -ve Days8192952107330
Stock -ve Days9152856123389

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity113,954,344
Short Interest: % Change Since 91520250.9%
Average Daily Volume60,455,578
Days-to-Cover Short Interest1.88
Basic Shares Quantity5,685,000,000
Short % of Basic Shares2.0%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/5/20255.2%4.5%5.4%
4/29/20253.2%3.6%2.5%
2/4/2025-1.3%-1.3%-1.0%
10/29/2024-1.4%-3.8%-9.3%
7/30/20242.2%-3.2%-6.2%
5/1/20246.1%8.4%11.7%
1/30/2024-1.7%-3.3%-1.6%
10/13/20233.6%-4.5%-8.5%
...
SUMMARY STATS   
# Positive131110
# Negative111314
Median Positive3.2%3.2%7.0%
Median Negative-1.4%-3.3%-5.1%
Max Positive6.1%11.7%26.4%
Max Negative-5.0%-6.4%-12.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025805202510-Q 6/29/2025
3312025505202510-Q 3/30/2025
12312024227202510-K 12/31/2024
93020241104202410-Q 9/29/2024
6302024805202410-Q 6/30/2024
3312024508202410-Q 3/31/2024
12312023222202410-K 12/31/2023
93020231108202310-Q 10/1/2023
6302023809202310-Q 7/2/2023
3312023510202310-Q 4/2/2023
12312022223202310-K 12/31/2022
93020221109202210-Q 10/2/2022
6302022810202210-Q 7/3/2022
3312022511202210-Q 4/3/2022
12312021224202210-K 12/31/2021
93020211112202110-Q 10/3/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0BLAYLOCK RONALD E 2142025Buy25.6519,457499,072710,685Form
1Gottlieb Scott 10312024Buy28.241,00028,240282,400Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.